Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDE4B | Q07343 | 12/20 | 0.57 |
| ▸ | MAPT | P10636 | 1/20 | 0.46 |
| ▸ | NSD2 | O96028 | 1/20 | 0.45 |
| ▸ | JAK2 | O60674 | 2/20 | 0.43 |
| ▸ | JAK3 | P52333 | 2/20 | 0.43 |
| ▸ | JAK1 | P23458 | 1/20 | 0.43 |
| ▸ | TYK2 | P29597 | 1/20 | 0.43 |
| ▸ | LRRK2 | Q5S007 | 1/20 | 0.42 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.42 |
| ▸ | MEN1 | O00255 | 1/20 | 0.42 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.42 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.42 |
| ▸ | PRMT5 | O14744 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4335687 | 0.91 | PDE4B (0.51) | PDE4BMAPTNSD2JAK2JAK3 | |
| SCHEMBL4931199 | 0.82 | PDE4B (0.43) | PDE4BNSD2KDM4EMEN1ALDH1A1 | |
| SCHEMBL4952531 | 0.81 | PDE4B (0.42) | PDE4BNSD2KDM4EMEN1ALDH1A1 | |
| SCHEMBL4494831 | 0.81 | PDE4B (0.57) | PDE4B | |
| SCHEMBL12363597 | 0.80 | PDE4B (0.67) | PDE4BMAPTJAK2JAK3MEN1 | |
| SCHEMBL14115743 | 0.80 | PDE4B (0.75) | PDE4BJAK2JAK3 | |
| SCHEMBL4951407 | 0.79 | MAPT (0.44) | PDE4BMAPTNSD2JAK2JAK3 | |
| SCHEMBL13609638 | 0.79 | PDE4B (0.65) | PDE4BMAPTJAK2JAK3MEN1 | |
| SCHEMBL4335271 | 0.79 | PDE4B (0.73) | PDE4BJAK2JAK3 | |
| Acetic Acid SCHEMBL5962835 | 0.78 | PDE4B (0.72) | PDE4BJAK2JAK3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080132536-A1 | PYRAZOLO [3,4-B] PYRIDINE COMPOUNDS, AND THEIR USE AS PDE4 INHIBITORS | GLAXO GROUP LIMITED | 2008-06-05 | — | — | US | disclosed |
| US-20070111995-A1 | Pyrazolo [3,4-B] pyridine Compounds and Their Use as Phosphodiesterase Inhibitors | GLAXO GROUP LIMITED (GB) | 2007-05-17 | — | — | US | disclosed |
| CN-1694882-A | Pyrazolo[3,4-b]pyridine compounds, and their use as phosphodiesterase inhibitors | GLAXO GROUP LTD (GB) | 2005-11-09 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080132536-A1 | PYRAZOLO [3,4-B] PYRIDINE COMPOUNDS, AND THEIR USE AS PDE4 INHIBITORS | PDE4A, PDE4B, PDE4C | PDE4B 2/4885MAPT 4415/4885NSD2 3950/4885 |
| US-20070111995-A1 | Pyrazolo [3,4-B] pyridine Compounds and Their Use as Phosphodiesterase Inhibitors | PDE4B, PDE3B, PDE4A | PDE4B 1/4885MAPT 4609/4885NSD2 2352/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.